Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

BACKGROUND: Venetoclax, a small molecule BH3 mimetic which inhibits the anti-apoptotic protein Bcl-2, and idasanutlin, a selective MDM2 antagonist, have both shown activity as single-agent treatments in pre-clinical and clinical studies in acute myeloid leukemia (AML). In this study, we deliver the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehmann, Christian, Friess, Thomas, Birzele, Fabian, Kiialainen, Anna, Dangl, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924270/
https://www.ncbi.nlm.nih.gov/pubmed/27353420
http://dx.doi.org/10.1186/s13045-016-0280-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924270/
https://www.ncbi.nlm.nih.gov/pubmed/27353420
http://dx.doi.org/10.1186/s13045-016-0280-3

Ejemplares similares